drugset / Trial / NCT04595162
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Phase 1
Not yet recruiting
12 enrolled
Peking University Third Hospital
Gracell Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 6-12 subjects to receive GC019F therapy.
Timeline
- Start
- 2021-03-15
- Primary completion
- 2023-12-15
- Completion
- 2035-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC019F | Cell therapy | — | Other |